Elke Rammant1, Piet Ost2, Martijn Swimberghe2, Barbara Vanderstraeten2, Nicolaas Lumen3, Karel Decaestecker3, Renée Bultijnck4, Gert De Meerleer4, Camille Sarrazyn4, Roos Colman5, Valérie Fonteyne2. 1. Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium. elke.rammant@uzgent.be. 2. Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium. 3. Department of Urology, Ghent University Hospital, Ghent, Belgium. 4. Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium. 5. Department of Public Health, Ghent University, Ghent, Belgium.
Abstract
PURPOSE: The risk of developing acute radiotherapy(RT)-induced side effects may increase with hypofractionated RT. To detect treatment-related side effects, patient-reported outcomes (PROs) might be more reliable than physician-reported outcomes. Therefore, we tried to evaluate the rate of agreement between urinary and gastrointestinal (GI) side effects and the prevalence of side effects reported by patients and by physicians. METHODS: Data from a randomized controlled trial (RCT) comparing two hypofractionated RT schedules were used. Urinary (nocturia, incontinence, frequency, dysuria, and urgency) and GI (obstruction, diarrhea, vomiting, nausea, bloating, hemorragia, and incontinence) symptoms measured by the EORTC QLQ-C30 and PR-25 were used for PROs. The same symptoms were scored by the physician using the Common Terminology Criteria Adverse Events v4.0. Outcomes were reported at baseline, end of treatment, month 1, and month 3. PROs and physician-reported outcomes were converted in two categories (0 = no symptoms; 1 = symptoms of any severity) and were correlated using the kappa (κ) correlation statistics. Values below 0.40 were considered low agreement. In addition, the prevalence of symptoms was calculated. RESULTS: Data from 160 patients were used. The mean value for Cohen's κ was 0.31 (ranging between 0.04 and 0.55) and 0.23 (ranging between 0.04 and 0.47) for urinary and GI symptoms, respectively. Except for three symptoms at baseline, all symptoms reported by patients were higher than those reported by physicians. CONCLUSION: There is low agreement between symptoms reported by patients and physicians, with high rates of underreporting by the physician.
RCT Entities:
PURPOSE: The risk of developing acute radiotherapy(RT)-induced side effects may increase with hypofractionated RT. To detect treatment-related side effects, patient-reported outcomes (PROs) might be more reliable than physician-reported outcomes. Therefore, we tried to evaluate the rate of agreement between urinary and gastrointestinal (GI) side effects and the prevalence of side effects reported by patients and by physicians. METHODS: Data from a randomized controlled trial (RCT) comparing two hypofractionated RT schedules were used. Urinary (nocturia, incontinence, frequency, dysuria, and urgency) and GI (obstruction, diarrhea, vomiting, nausea, bloating, hemorragia, and incontinence) symptoms measured by the EORTC QLQ-C30 and PR-25 were used for PROs. The same symptoms were scored by the physician using the Common Terminology Criteria Adverse Events v4.0. Outcomes were reported at baseline, end of treatment, month 1, and month 3. PROs and physician-reported outcomes were converted in two categories (0 = no symptoms; 1 = symptoms of any severity) and were correlated using the kappa (κ) correlation statistics. Values below 0.40 were considered low agreement. In addition, the prevalence of symptoms was calculated. RESULTS: Data from 160 patients were used. The mean value for Cohen's κ was 0.31 (ranging between 0.04 and 0.55) and 0.23 (ranging between 0.04 and 0.47) for urinary and GI symptoms, respectively. Except for three symptoms at baseline, all symptoms reported by patients were higher than those reported by physicians. CONCLUSION: There is low agreement between symptoms reported by patients and physicians, with high rates of underreporting by the physician.
Entities:
Keywords:
Patient-reported outcomes; Prostate cancer; Quality of life; Radiotherapy; Urinary and gastrointestinal toxicity
Authors: Patricia Mae G Santos; Andrew R Barsky; Wei-Ting Hwang; Curtiland Deville; Xingmei Wang; Stefan Both; Justin E Bekelman; John P Christodouleas; Neha Vapiwala Journal: Cancer Date: 2019-09-10 Impact factor: 6.860
Authors: Luca F Valle; Dan Ruan; Audrey Dang; Rebecca G Levin-Epstein; Ankur P Patel; Joanne B Weidhaas; Nicholas G Nickols; Percy P Lee; Daniel A Low; X Sharon Qi; Christopher R King; Michael L Steinberg; Patrick A Kupelian; Minsong Cao; Amar U Kishan Journal: Front Oncol Date: 2020-05-20 Impact factor: 6.244
Authors: Finbar Slevin; Sree Lakshmi Rodda; Peter Bownes; Louise Murray; David Bottomley; Clare Wilkinson; Ese Adiotomre; Bashar Al-Qaisieh; Emma Dugdale; Oliver Hulson; Joshua Mason; Jonathan Smith; Ann M Henry Journal: Clin Transl Radiat Oncol Date: 2019-10-14
Authors: Sarthak Shah; Tamir Sholklapper; Michael Creswell; Abigail Pepin; Jonathan Cantalino; Ryan Andrew Hankins; Simeng Suy; Sean P Collins Journal: Front Oncol Date: 2021-11-25 Impact factor: 6.244
Authors: Roman O Kowalchuk; David Hillman; Thomas B Daniels; Carlos E Vargas; Jean-Claude M Rwigema; William W Wong; Bradley J Stish; Amylou C Dueck; Richard Choo Journal: Clin Transl Radiat Oncol Date: 2021-09-15
Authors: Darren M C Poon; Daisy Lam; Kenneth C W Wong; Cheuk-Man Chu; Michael Cheung; Frankie Mo; Joyce Suen; Chi-Fai Ng; Anthony T C Chan Journal: Curr Oncol Date: 2021-12-22 Impact factor: 3.677